Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
117 107.9 119.1 124.6 118.5 Last
38038890 45715500 55110050 45735730 28349040 Volume
-9.79% -7.78% +10.38% +4.62% -4.90% Change
Estimated financial data (e)
Sales 2021 9 100 M 1 408 M 1 408 M
Net income 2021 2 544 M 394 M 394 M
Net cash position 2021 3 974 M 615 M 615 M
P/E ratio 2021 160x
Yield 2021 -
Sales 2022 13 291 M 2 057 M 2 057 M
Net income 2022 3 728 M 577 M 577 M
Net cash position 2022 2 297 M 356 M 356 M
P/E ratio 2022 111x
Yield 2022 -
Capitalization 417 B 64 616 M 64 619 M
EV / Sales 2021 45,4x
EV / Sales 2022 31,2x
Nbr of Employees 6 646
Free-Float 82,5%
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Sector
Pharmaceuticals
Calendar
08/23Earnings Release
More about the company
Ratings of WuXi Biologics (Cayman) Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about WUXI BIOLOGICS (CAYMAN) INC.
07/26Wuxi Biologics Receives Commercial Manufacturing License from German Health A..
CI
07/21WUXI BIOLOGICS CAYMAN : Stockholder Divests $1.3 Billion Stake; Shares Slide 3%
MT
07/14WUXI BIOLOGICS CAYMAN : Adlai Nortye Raises $100 Million in Series D Financing, ..
AQ
07/13WUXI BIOLOGICS CAYMAN : Forecasts over 135% Surge in H1 Profit; Shares Jump 6%
MT
07/13WuXi Biologics Inc. Provides Unaudited Consolidated Earnings Guidance for the..
CI
07/13Hong Kong shares end higher on tech, financial rally
RE
07/07Hong Kong stocks close at 8-week low as internet firms drag
RE
07/06Chinese Pharma Stocks Drop on Proposed New Rules for Oncology Drug Trials
DJ
07/06Hong Kong shares slip as healthcare stocks drop in line with mainland peers
RE
06/18Hong Kong stocks post weekly loss after Fed's hawkish turn
RE
06/16Wuxi Biologics Inc. Announces Board Changes
CI
06/02Hong Kong stocks end lower as blue-chip tech, healthcare firms retreat
RE
05/26WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
CI
05/20WUXI BIOLOGICS CAYMAN : Pumps More Cash into Biotech Firm Duality Biologics
MT
05/14WUXI BIOLOGICS CAYMAN : Notification letter and request form to non-registered h..
PU
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) INC.
04/27MÄRKTE ASIEN/Wenig Bewegung - Musik spielt bei Einzelwerten
04/27MÄRKTE ASIEN/Kleine Einbußen querbeet - Posco weiter fest
03/22STOCK MARKET PARIS : L'Amérique accélère, l'Europe s'enlise
03/22EN DIRECT DES MARCHES  : Veolia / Suez, Faurecia, Valneva, Quadient, Credit Suis..
03/17Le funambule Powell remonte en première ligne
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 98,51 CNY
Average target price 122,67 CNY
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Chief Executive Officer & Executive Director
Shao Hua Lu-Wong Chief Financial Officer
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
William Robert Keller Independent Non-Executive Director
Sector and Competitors